Currently, the gold standard biomarkers for Alzheimer’s disease diagnosis in clinical practice are CSF amyloid-β (Aβ), phosphorylated tau, and total tau, supported by advanced neuroimaging methods and positron emission tomography (PET). Here, MAPT is linked to early-onset autosomal dominant Alzheimer disease.